{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T15:53:00Z","timestamp":1724860380800},"reference-count":60,"publisher":"SLACK, Inc.","issue":"S1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Refract Surg"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>The purpose of this article is to review the current status of presbyopia amelioration with surgical and pharmacologic procedures that partially compensate for loss of accommodation in advance of cataract surgery and lens replacement. Over the last few years, several corneal surgical and topical pharmacological approaches for the treatment of presbyopia have been introduced to the marketplace or are in the developmental pipeline. The approaches vary in invasiveness, duration of effect, reversibility, risk\/benefit ratio, and clinical results. The advantages and disadvantages for each are discussed. Corneal surgical interventions aim to provide improved near and intermediate vision in patients with presbyopia through refractive means that extend ocular depth of focus through shape modification. The use of miotic drops or corneal lamellar implants extend depth of focus with the \u201cpinhole\u201d aperture size reduction effect. Unlike in adults younger than 40 years, the refractive status of the patient with presbyopia is not stable. Hence, procedures that provide a permanent refractive change may not provide long-term full correction; eye drops or other treatments that are self-reversing in time or are easily reversible may be used as needed. On the horizon, procedures are being explored that may add years of functional lens accommodation by preserving the deformable gel properties of the lens.<\/jats:p>\n          <jats:p>\n            <jats:bold>\n              [\n              <jats:italic>J Refract Surg<\/jats:italic>\n              . 2021;37(6 Suppl):S20\u2013S27.]\n            <\/jats:bold>\n          <\/jats:p>","DOI":"10.3928\/1081597x-20210408-04","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T17:37:45Z","timestamp":1624642665000},"source":"Crossref","is-referenced-by-count":9,"title":["Advances in Corneal Surgical and Pharmacological Approaches to the Treatment of Presbyopia"],"prefix":"10.3928","volume":"37","author":[{"given":"Marguerite B.","family":"McDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Mychajlyszyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Mychajlyszyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Klyce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2308","reference":[{"key":"e_1_3_2_2_2","first-page":"132","article-title":"Studies in monocular and binocular accommodation, with their clinical application","volume":"20","author":"Duane A","year":"1922","unstructured":"Duane A. Studies in monocular and binocular accommodation, with their clinical application. Trans Am Ophthalmol Soc. 1922;20:132\u2013157.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2018.09.004"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.126.12.1731"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)00502-3"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0270-0255(86)90146-6"},{"issue":"8","key":"e_1_3_2_7_2","first-page":"2566","article-title":"Changes in refraction over 10 years in an adult population: the Beaver Dam Eye Study","volume":"43","author":"Lee KE","year":"2002","unstructured":"Lee KE, Klein BEK, Klein R, Wong T-Y. Changes in refraction over 10 years in an adult population: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. 2002;43(8):2566\u20132571.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S72676"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20131223-01"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000000002"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(01)00647-9"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081-597X-20060501-06"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20080501-07"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20120723-01"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12346"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_32_20"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20090917-05"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-307672"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1364\/BOE.10.000855"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2017.08.018"},{"key":"e_1_3_2_21_2","unstructured":"Cataract & Refractive Surgery Today Laser induced refractive index change"},{"key":"e_1_3_2_22_2","first-page":"10","article-title":"Queratoplastia refractiva","volume":"2","author":"Barraquer JI","year":"1949","unstructured":"Barraquer JI. Queratoplastia refractiva. Estudios e Informaciones Oftalmologicas. 1949;2:10.","journal-title":"Estudios e Informaciones Oftalmologicas"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0b013e31820f2071"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(85)33849-6"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20170111-03"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2018.02.023"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2011.10.033"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20140217-04"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20110802-02"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20180308-01"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2018.11.003"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.3928\/1081597X-20150623-03"},{"key":"e_1_3_2_33_2","unstructured":"U.S. Food & Drug Administration. RVO 2.0 Inc. recalls Raindrop Near Vision Inlay due to risk of increased risk of corneal haze. Accessed January 1 2021. https:\/\/www.fda.gov\/medical-devices\/medical-device-recalls\/rvo-20-inc-recalls-raindrop-near-vision-inlay-due-risk-increased-risk-corneal-haze"},{"key":"e_1_3_2_34_2","unstructured":"U.S. National Library of Medicine. Investigation of the Presbia Flexivue MicrolensTM. NCT02110472. Accessed January 1 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02110472"},{"key":"e_1_3_2_35_2","unstructured":"Perriello B. Presbia abandons Flexivue microlens lays off all but 3. MassDevice. April 23 2019. Accessed January 1 2021. https:\/\/www.massdevice.com\/presbia-abandons-flexivue-microlens-lays-off-all-but-3\/"},{"issue":"2","key":"e_1_3_2_36_2","first-page":"S277","article-title":"Holmium:YAG laser thermokeratoplasty for hyperopia","volume":"10","author":"Durrie DS","year":"1994","unstructured":"Durrie DS, Schumer DJ, Cavanaugh TB. Holmium:YAG laser thermokeratoplasty for hyperopia. J Refract Corneal Surg. 1994;10(2 Suppl):S277\u2013S280.","journal-title":"J Refract Corneal Surg"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(02)01255-1"},{"key":"e_1_3_2_38_2","first-page":"412","article-title":"Optics of conductive keratoplasty: implications for presbyopia management","volume":"103","author":"Hersh PS","year":"2005","unstructured":"Hersh PS. Optics of conductive keratoplasty: implications for presbyopia management. Trans Am Ophthalmol Soc. 2005;103:412\u2013456.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_3_2_39_2","article-title":"Improved method of laser thermal keratoplasty to overcome presbyopia","author":"Rodgers KJ","year":"2011","unstructured":"Rodgers KJ, Glen HG, Salz JJ, Maguen E, Berry MJ. Improved method of laser thermal keratoplasty to overcome presbyopia. Proc SPIE Volume 7885: Ophthalmic Technologies XXI. February 11, 2011.","journal-title":"Proc SPIE Volume 7885: Ophthalmic Technologies XXI"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7545687"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1444-0938.1999.tb06654.x"},{"key":"e_1_3_2_42_2","unstructured":"Orasis Pharmaceuticals CSF-1 overview"},{"key":"e_1_3_2_43_2","unstructured":"U.S. National Library of Medicine. A multi-center double-masked evaluation of the efficacy and safety of CSF-1 in the treatment of presbyopia. NCT03885011. Accessed January 1 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03885011"},{"key":"e_1_3_2_44_2","unstructured":"Orasis Pharmaceuticals 2019 Orasis Pharmaceuticals announces CSF-1 eye drop successfully met primary endpoint in phase 2b clinical study in presbyopia"},{"key":"e_1_3_2_45_2","unstructured":"U.S. National Library of Medicine. Safety & efficacy of pilocarpine eye solutions for temporary improvement of near vision in presbyopic adults (VISION-1). NCT04657172. Accessed January 1 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04657172"},{"key":"e_1_3_2_46_2","unstructured":"Eyenovia announces FDA acceptance of IND for MicroLine for presbyopia clearing path to initiate phase 3 VISION trial by year end. December 3 2020. Accessed January 1 2021. https:\/\/ir.eyenovia.com\/node\/8216\/pdf"},{"key":"e_1_3_2_47_2","unstructured":"U.S. National Library of Medicine. Evaluation of the efficacy and safety of PRX-100 in the treatment of early to moderate presbyopia. NCT02554396. Accessed January 1 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02554396"},{"key":"e_1_3_2_48_2","article-title":"Pending presbyopia treatments edge closer to disrupting the marketspace","author":"Linnehan R","year":"2019","unstructured":"Linnehan R. Pending presbyopia treatments edge closer to disrupting the marketspace. Ocular Surgery News. March 18, 2019. Accessed January 1, 2021. https:\/\/www.healio.com\/news\/ophthalmology\/20190313\/pending-presbyopia-treatments-edge-closer-to-disrupting-the-marketspace","journal-title":"Ocular Surgery News"},{"key":"e_1_3_2_49_2","unstructured":"U.S. National Library of Medicine. Phase 3 efficacy study of AGN-190584 in participants with presbyopia. NCT03804268 NCT03857542. Accessed January 1 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03804268 NCT03857542"},{"key":"e_1_3_2_50_2","unstructured":"Allergan an AbbVie Company announces positive phase 3 topline results for investigational AGN-190584 for the treatment of presbyopia. October 28 2020. Accessed January 1 2021. https:\/\/www.prnewswire.com\/news-releases\/allergan-an-abbvie-company-announces-positive-phase-3-topline-results-for-investigational-agn-190584-for-the-treatment-of-presbyopia-301161348.html"},{"key":"e_1_3_2_51_2","unstructured":"Kaufman HE inventor; Visus Therapeutics Inc assignee. Preparations and methods for ameliorating or reducing presbyopia. US patent 8 455 494 B2. June 4 2013."},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000137"},{"key":"e_1_3_2_53_2","unstructured":"LUMIFY Redness Reliever Eye Drops. Bausch + Lomb. Accessed January 1 2021. https:\/\/www.bausch.com\/ecp\/our-products\/otcophthalmics\/lumify-drops"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40662-016-0065-3"},{"key":"e_1_3_2_55_2","unstructured":"U.S. National Library of Medicine. Safety and efficacy of ophthalmic phentolamine mesylate in glaucoma. NCT03960866 NCT04004507 NCT04024891. Accessed January 1 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03960866 NCT04004507 NCT04024891."},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S278169"},{"key":"e_1_3_2_57_2","unstructured":"U.S. National Library of Medicine. Safety and efficacy of Nyxol with pilocarpine eye drops in subjects with presbyopia. NCT04675151. Accessed February 19 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04675151"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-18413"},{"key":"e_1_3_2_59_2","unstructured":"U.S. National Library of Medicine. A study of safety and efficacy of UNR844 chloride (UNR844-Cl) eye drops in subjects with presbyopia. NCT03809611. Accessed January 1 2021. https:\/\/clinical-trials.gov\/ct2\/show\/NCT03809611"},{"key":"e_1_3_2_60_2","article-title":"A 3-month, randomized, placebo-controlled, double-masked, multi-center study to evaluate the safety and efficacy of topical ocular UNR844-Cl in subjects with presbyopia","author":"U.S. National Library of Medicine","year":"2019","unstructured":"U.S. National Library of Medicine. A 3-month, randomized, placebo-controlled, double-masked, multi-center study to evaluate the safety and efficacy of topical ocular UNR844-Cl in subjects with presbyopia. July 2, 2019. Clinical Trial Protocol. Accessed January 1, 2021. https:\/\/clinicaltrials.gov\/ProvidedDocs\/11\/NCT03809611\/Prot_000.pdf","journal-title":"Clinical Trial Protocol"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2016.07.012"}],"container-title":["Journal of Refractive Surgery"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T03:53:46Z","timestamp":1683086026000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.healio.com\/doi\/10.3928\/1081597X-20210408-04"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":60,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.3928\/1081597X-20210408-04"],"URL":"https:\/\/doi.org\/10.3928\/1081597x-20210408-04","relation":{},"ISSN":["1081-597X"],"issn-type":[{"value":"1081-597X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}